MONDAY, Feb. 24, 2025 (HealthDay news) — Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, a new study suggests. People with new knees and hips are significantly less likely to need follow-up surgery to fix wear and tear on their artificial joint if they lose weight using Wegovy, Zepbound or other GLP-1 drugs, researchers reported in a new study published Feb. 21 in JAMA Network Open. Patients who lost 2% to 10% of their initial weight had an overall 25% lower risk of follow-up surgery, and those who lost 10% or more had a 43% lower risk. “A higher proportion of weight loss after initiating antiobesity medications within 1 year was associated with a lower risk of 5-year and 10-year revision among patients with obesity undergoing joint replacement,” concluded the research team led by Dr. Chao Zeng, an orthopedics specialist with Ziangya Hospital at Central South University in Changsha, China. “These results suggest that antiobesity medication use, with relatively safe and sustainable weight loss, may be an effective strategy for improving implant survivorship of hip and knee replacement in the obese population,” researchers added. In the U.S., about 900,000 knee replacement surgeries and 400,000 hip replacements occur each year, researchers said in background notes. Knee replacements can be expected to function well for… read on > read on >

















